Israel’s Teva Pharmaceutical, the world’s largest generic drugmaker, announced on Saturday that it would begin marketing “Ajovy,” a preventive drug against migraine, after it received approval from the U.S. Food and Drug Administration (FDA).
Migraine is a common form of headache, usually very intensive and restricts the activity. It is a phenomenon of the nervous system that cannot be predicted in advance.
Ajovy is the first drug for migraine that allows one injection for three months, compared with the U.S. company Amgen’s “Aimovig” drug, which should be injected once a month.
These are the only two drugs that treat migraine through an antibody blocking the protein CGRP (calcitonin gene-related peptide), which participates in the pain mechanism.
Ajovy can be injected every three months at a dose of 675 milligrams, or once a month at a dose of 225 mg. The injection is given in the patient’s home independently or at the clinic.